Modality
Nanobody
MOA
KIF18Ai
Target
IL-23
Pathway
Fibrosis
GA
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
Aug 2020
→ May 2029
Phase 2Current
NCT05235517
227 pts·GA
2020-08→2029-05·Active
NCT06970166
1,842 pts·GA
2025-03→2026-01·Terminated
2,069 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-222mo agoPh3 Readout· GA
2029-05-243.1y awayPh3 Readout· GA
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2/3
Active
P2/3
Termina…
Catalysts
Ph3 Readout
2026-01-22 · 2mo ago
GA
Ph3 Readout
2029-05-24 · 3.1y away
GA
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05235517 | Phase 2/3 | GA | Active | 227 | MRD |
| NCT06970166 | Phase 2/3 | GA | Terminated | 1842 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 |